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Caspase-8 is best known for its cell death function via death receptors. Recent evidence 
indicates that caspase-8 also has nonapoptotic functions. Caspase-8 deficiency is associated 
with pathologies that are unexpected for a proapoptotic molecule, such as abrogation 
of activation-induced lymphocyte proliferation, perturbed immune homeostasis, and 
immunodeficiency. In this study, we report the long-term physiological consequences of 
T cell–specific deletion of caspase-8 (
 
tcasp8
 
 
 
/
 
 
 
). We show that 
 
tcasp8
 
 
 
/
 
 
 
 mice develop 
an age-dependent lethal lymphoproliferative and lymphoinfiltrative immune disorder 
characterized by lymphoadenopathy, splenomegaly, and accumulation of T cell infiltrates in the 
lungs, liver, and kidneys. Peripheral 
 
casp8
 
 
 
/
 
 
 
 T cells manifest activation marker up-regulation 
and are proliferating in the absence of any infection or stimulation. We also provide evidence 
suggesting that this immune disorder is different from the autoimmune lymphoproliferative 
syndrome. Interestingly, the condition described in 
 
tcasp8
 
 
 
/
 
 
 
 mice manifests features 
consistent with the disorder described in humans with 
 
Caspase-8
 
 deficiency. These findings 
suggest that 
 
tcasp8
 
 
 
/
 
 
 
 mice may serve as an animal model to evaluate Caspase-8–deficient 
patient prognosis and therapy. Overall, our study uncovers novel in vivo functions for 
caspase-8 in immune regulation.
 
Caspase-8, an aspartate-specific cysteine protease,
is best known for its role in mediating cell
death through death receptors such as CD95
(Fas/Apo1) (1–3). Recent evidence supports a
new paradigm that suggests that caspase-8 also
has nonapoptotic functions in the transduction
of signals via the T cell receptor, B cell receptor,
and Toll-like receptors (4–7). Despite extensive
characterization of the biochemical and cellular
functions of caspase-8, its physiological role is
largely unknown. A recent study reported that
humans with a germline point mutation of
 
Caspase-8
 
 manifested lymphoadenopathy and
splenomegaly—conditions normally associated
with autoimmunity (5). Somewhat paradoxi-
cally, these patients were also concluded to be
immunodeficient and succumbed frequently to
microbial infections as a result of their inability
to activate T, B, and NK
 
 
 
cells (5). Thus, loss of
caspase-8 leads to a complex immune condition
manifesting features of immunodeficiency and
autoimmunity.
Because 
 
caspase-8
 
 deletion is associated
with embryonic lethality in mice (7–9), we
used the 
 
loxp/Cre recombinase
 
 system to gener-
ate 
 
tcasp8
 
 
 
/
 
 
 
 mice (6). In keeping with its role
as an effector of apoptosis, 
 
casp8
 
 
 
/
 
 
 
 T cells
were refractory to cell death induced by
CD95. However, caspase-8 deficiency was also
associated with T cell lymphopenia, defective
activation-induced T cell proliferation, and de-
fective T cell responses to viral infection.
 
tcasp8
 
 
 
/
 
 
 
 mice were concluded to be immuno-
deficient, which recapitulated the immunodefi-
ciency identified in humans with 
 
Caspase-8
 
mutation (5, 6).
We now report that 
 
tcasp8
 
 
 
/
 
 
 
 mice devel-
oped an age-dependent lethal lymphoprolifera-
tive  and lymphoinfiltrative immune disorder.
With age, 
 
tcasp8
 
 
 
/
 
 
 
 mice developed lym-
phoadenopathy, splenomegaly, and accumulated
nonclonal T cell infiltrates in the lungs, liver,
and kidneys accompanied by tissue damage.
Furthermore, T cells isolated from old 
 
tcasp8
 
 
 
/
 
 
 
mice were in a perpetual state of activation,
which could account for the observed patho-
logical phenotypes. This study uncovers novel
physiological functions for caspase-8 in immune
regulation and function.
 
RESULTS AND DISCUSSION
 
In this study, we monitored a cohort of aging
 
tcasp8
 
 
 
/
 
 
 
 mice. Mice were considered “old”
after 8 wk of age and were designated
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“
 
Otcasp8
 
 
 
/
 
 
 
” for “
 
Old-tcasp8
 
 
 
/
 
 
 
.” 
 
Otcasp8
 
 
 
/
 
 
 
 mice were
visibly smaller, often appeared weak, and weighed signifi-
cantly less than their 
 
casp8
 
fl/fl
 
 control littermates (Fig. 1 A).
The survival of 
 
Otcasp8
 
 
 
/
 
 
 
 mice was reduced compared
with 
 
control
 
 littermates; 
 
Otcasp8
 
 
 
/
 
 
 
 mice perished at an aver-
age age of 51.7 wk with lethality observed as early as 14 wk,
whereas control mice lived, on average, for 
 
 
 
100 wk (Fig. 1
B). Furthermore, a predominant feature manifested in
 
Otcasp8
 
 
 
/
 
 
 
 mice was chronic splenomegaly and/or lym-
phoadenopathy (Fig. 1 C). Based on these observations, we
reasoned that the lethality observed in 
 
Otcasp8
 
 
 
/
 
 
 
 mice may
be due to defective homeostasis leading to a prominent im-
mune disorder.
To investigate this disorder, lymphoid and nonlymphoid
organs were dissected from 
 
Otcasp8
 
 
 
/
 
 
 
 mice and analyzed.
Gross observation of thymi from control and 
 
Otcasp8
 
 
 
/
 
 
 
mice showed no difference in size at all ages (Fig. S1
A, available at http://www.jem.org/cgi/content/full/
jem.20050683/DC1). Thymocyte subpopulations and sur-
face expression of the CD4, CD8, CD44, CD25, CD69 and
CD95 were similar in 
 
Otcasp8
 
 
 
/
 
 
 
 and control littermates
(Fig. S1 B). In contrast, analysis of peripheral lymphocyte
populations from spleen and LNs identified a decreased
B-to-T cell ratio and a decreased proportion of CD8
 
 
 
 T
cells relative to CD4
 
 
 
 T cells in 
 
Otcasp8
 
 
 
/
 
 
 
 mice compared
with 
 
controls
 
 (Fig. 2 A and Table S1, available at http://
www.jem.org/cgi/content/full/jem.20050683/DC1); this is
consistent with the observations made in young 
 
tcasp8
 
 
 
/
 
 
 
mice (
 
Ytcasp8
 
 
 
/
 
 
 
) (6). Surprisingly, the peripheral T cell
lymphopenia reported in 
 
Ytcasp8
 
 
 
/
 
 
 
 mice (6) was no longer
apparent in 
 
Otcasp8
 
 
 
/
 
 
 
 mice (Fig. 2 B). Lymphoproliferation
in 
 
Otcasp8
 
 
 
/
 
 
 
 mice was initially identified by splenomegaly
and lymphoadenopathy and confirmed by increased total
lymphocyte counts (Fig. 2 B). Furthermore, the age-depen-
dent expansion of total lymphocyte numbers was more pro-
nounced in 
 
Otcasp8
 
 
 
/
 
 
 
 mice compared with littermate con-
trols (Fig. 2 B). These data, together with FACS
 
 
 
(Becton
Dickinson) analysis of splenocytes and LN cells, shows that
the B cell to T cell ratio does not vary with age, yet lym-
phoid hyperplasia is apparent in 
 
Otcasp8
 
 
 
/
 
 
 
 mice. Therefore,
 
tcasp8
 
 
 
/
 
 
 
 mice show two distinct phenotypes: peripheral T
cell lymphopenia early in life and in older mice. Although
the decreased T cell to B cell ratio is maintained, caspase-8
Figure 1. Decreased weight and decreased viability in old tcasp8 /  
mice. (A) Representative mice demonstrate relative sizes of old casp8fl/fl;
LckCre (Otcasp8 / ) mice compared with casp8fl/fl control mice. Old 
tcasp8 /  (nmale   5, n female   14) weighed significantly less than their 
casp8fl/fl control littermates (nmale   5, nfemale   10). All mice were  24 wk 
old. Error bars represent the mean   SEM as described in Materials and 
methods. *, P   0.05. (B) Kaplan-Meier analysis represents the percent 
survival of control (n   18) and tcasp8 /  (n   15) cohort mice versus age 
in weeks. (C) Representative LN and spleens demonstrate lymphoadenopathy 
and splenomegaly in old tcasp8 /  mice. An asterisk indicates statistical 
significance.
Figure 2. Lymphoproliferation in old tcasp8 /  mice. (A) Representative 
flow cytometric analysis identified the proportion of T cells (Thy1.2 ) versus B 
cells (B220 ) and the proportion of CD4  (Thy1.2 CD4 ) versus CD8  
(Thy1.2 CD8 ) T cells in control, tcasp8 / , and lpr mice. Numbers represent 
percentage of cells per quandrant. (B) Total lymphocyte, total B cell, and 
total T cell counts were evaluated in the LNs (top left) and spleen (top 
right). Total lymphocyte counts in the LNs and spleen were plotted against 
mouse age (bottom left and right, respectively). A line of best-fit was plotted 
on each graph. Error bars represent the mean   SEM as described in 
Materials and methods.JEM VOL. 202, September 19, 2005 729
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deficiency is associated with a balanced expansion of both T
and B lymphocyte numbers in the periphery. The accumula-
tion of B cells, despite the fact that caspase-8 is deficient only
in T cells, suggests that expansion of B cell populations are
secondary to and dependent on changes in mutant T cells—
implying that caspase-8 is required for regulating lympho-
cyte homeostasis, possibly through control of autocrine T
cell signals and signaling to B cells.
Examination of nonlymphoid organs via histology and
immunohistochemistry identified unusual T cell infiltration
in the liver, lungs, and kidneys of Otcasp8 /  mice com-
pared with control mice (Fig. 3; and Fig. S2 and Fig. S3
A, available at http://www.jem.org/cgi/content/full/
jem.20050683/DC1). Livers from 30-wk-old Otcasp8 / 
mice displayed T cell accumulation as focal perivascular infil-
trates (Fig. 3 A, iv and vii–viii, and Fig. S2 A). Similarly,
lungs of Otcasp8 /  mice contained obvious interstitial peri-
bronchiovascular T cell infiltration (Fig. 3 A, vi; and Fig. S2).
Kidneys from Otcasp8 /  mice also manifested focal intersti-
tial and periglomerular T cell infiltration (Fig. 3 A, v and
ix–x; and Fig. S2). Increased infiltration of T cells to the
liver, kidneys, and lung of Otcasp8 /  mice was confirmed via
FACS analysis (Fig. 3 B). T cell infiltration was observed as
early as 20 wk of age and progressed as Otcasp8 /  mice grew
older (Fig. 3 C). At approximately 1 yr of age, disrupted lung
tissue organization was associated with much more wide-
Figure 3. Age-dependent multitissue T cell infiltration in old 
tcasp8 /  mice. (A) Liver (i, iv), kidney (ii, v), and lung (iii, vi) sections from 
30-wk-old mice were immunohistochemically stained with anti-B220 
antibodies (to reveal B cells) and anti-CD3 antibodies (to reveal T cells). 
Consecutive liver and kidney sections stained with hematoxylin-eosin 
(vii, ix) and anti-CD3 (viii, x) demonstrate focal interstitial T cell accumulation 
in perivascular (vii, viii) or periglomerular (ix, x) areas, respectively. (B) Single 
cell suspensions were prepared from the liver, kidneys, and lungs, and 
T cell infiltrates were quantitated via flow cytometry. This analysis was 
repeated in a minimum of three mice per genotype. Error bars represent 
the mean   SEM as described in Materials and methods. **, P   0.00486. 
(C) Analysis of lung tissue from 6-wk-old (i, iv), 20-wk-old (ii, v), and 
50-wk-old (iii, vi) control (i–iii) and tcasp8 /  (iv–vi) mice with anti-CD3 
antibodies demonstrates an age-dependent increase in T cell infiltration. 
Lung tissues from control mice appear relatively normal at all ages (i–iii), 
whereas abnormal tissue is observed in the lung sections of 50-wk-old 
tcasp8 /  mice (vi). Black arrowheads indicate areas of focal T cell 
accumulation. Bars indicate 0.1 mm.
Figure 4. Infiltrating and circulating T cells from old tcasp8 /  
mice are proliferating and activated. In vivo BrdU incorporation was 
determined after injecting BrdU into mice. (A) Pulmonary T cell infiltrates 
in old tcasp8 /  mice contained actively proliferating T cells as determined 
immunohistochemically via BrdU staining and Ki67 labeling. (B) Examination 
of circulating T cells via flow cytometry revealed a greater proportion of 
BrdU  cells in each of the CD4 , CD8 , and B220  lymphocyte compartments 
of old tcasp8 /  mice. (C) BrdU incorporation in CD4 , CD8 , and B220  
lymphocytes was quantitated (n   3) for each genotype. Error bars represent 
the mean   SEM as described in Materials and methods. (D) Representative 
flow cytometry analysis of activation markers in peripheral T cells isolated 
from lymphoid organs isolated from old tcasp8 /  mice and littermate 
controls. Cell surface expression of the activation markers CD69, CD44, 
CD25, and CD95 and the T cell memory marker CD62L on both CD4  and 
CD8  subsets of T cells are shown.CASPASE-8 DEFICIENCY LEADS TO IMMUNE DISORDER | Salmena and Hakem 730
spread and abundant T cell infiltration (Fig. 3 C, iv–vi) com-
pared with controls (Fig. 3 C, i–iii). Abnormal T cell infil-
trates were absent in other nonlymphoid organs, including
the brain, heart, pancreas, and stomach (Fig. S2). T cell infil-
trates were not observed in control mice, and minimal B cell
presence was detected in the nonlymphoid organs of control
or Otcasp8 /  mice (Fig. 3 A, i–iii and iv; and Fig. S2). To
address the self-reactivity of casp8 /  T cells, we measured
the serum levels of alanine aminotransferase (ALT) and aspar-
tate aminotransferase (AST) as a measure of T cell–induced
damage to hepatocytes. No increases in serum levels of ALT
and AST were detected in Otcasp8 /  mice, suggesting that
either the levels of tissue damage are low and undetectable or
that no tissue damage is occurring (unpublished data). With
respect to the clonality of infiltrating T cells, detection of
CD4  and CD8  T cells in lung infiltrates and various V 
chains of the TCR on circulating T cells demonstrates the
polyclonal nature of this immune disorder (Fig. S3, A and B).
To determine the proliferative status of infiltrating and cir-
culating lymphocytes, we performed in vivo 5-bromo-
2 -deoxyuridine (BrdU) staining in Otcasp8 /  and control
mice. We observed that pulmonary T cell infiltrates in
Otcasp8 /  mice contained actively proliferating T cells as de-
termined immunohistochemically with anti-BrdU and anti-
Ki67 antibodies (Fig. 4 A). Examination of freshly isolated T
cells from Otcasp8 /  mice via flow cytometry revealed a
greater proportion of BrdU  cells in CD4 , CD8 , and
B220  lymphocytes (Fig. 4, B and C). Furthermore, we ob-
served an up-regulation of the cell surface activation markers
CD69, CD44, CD25, and CD95 on both CD4  and CD8 
T cells derived from Otcasp8 /  compared with control mice
(Fig. 4 D). Accordingly, decreased detection of the T cell
memory marker CD62L on Otcasp8 /  T cells indicated a
previous T cell activation event (Fig. 4 D). Otcasp8 /  T cells
express the same cell surface markers as antigen-activated T
cells in contrast to homeostatically proliferating T cells—
which, as shown in a recent publication, do not show this cell
surface marker profile (10). Infiltrating T cells from the livers
of Otcasp8 /  mice also displayed increased activation marker
expression (unpublished data). Similar to mice with T cell–
specific ablation of CD95, Otcasp8 /  mice older than 6 mo
of age consistently displayed increased expression of activation
markers on circulating T cells, and no such activation was ob-
served in littermate control mice (11). By contrast, no indica-
tors of activation were identified on B cells isolated from
Otcasp8 /  mice (Fig. S4, available at http://www.jem.org/
cgi/content/full/jem.20050683/DC1). These data suggest
that Otcasp8 / -derived T cells are activated in vivo.
Because Otcasp8 / -derived T cells are clearly proliferat-
ing in vivo, we investigated whether these T cells may have
overcome the proliferation defect observed in Ytcasp8 / 
mice (6). Similar to Ytcasp8 / -derived T cells, Otcasp8 / -
derived T cells had defective in vitro proliferative responses
to various stimuli (anti-CD3, anti-CD3, and CD28; anti-
CD3 and IL2) relative to controls (Fig. S5, available at http://
www.jem.org/cgi/content/full/jem.20050683/DC1). Fur-
thermore, activated Otcasp8 / -derived T cells were resis-
tant to CD95L-induced apoptosis as expected (unpublished
data). Therefore, in vitro experiments with casp8 /  T cells
derived from old mice show that the defective proliferation
and inhibition of CD95-mediated death are independent of
age. In contrast, the increased expression of activation mark-
ers and BrdU labeling show that circulating and infiltrating
Otcasp8 /  T cells are indeed activated and proliferate in
vivo. Although currently unclear, we propose that casp8 / 
T cells accumulate in vivo with age, perhaps because of their
inability to be eliminated by CD95-induced apoptosis and/
or activation-induced cell death. Furthermore, casp8 /  T
cells may accumulate due to a proliferative process related to
their activation status. It appears that the increased popula-
tion of activated T cells in Otcasp8 /  mice may be a result
of a phenomenon that includes both lymphoproliferation (as
determined by BrdU labeling and Ki67 staining) and lym-
phoaccumulation (due to the impaired CD95 death path-
way). Overall, we show that Otcasp8 /  mice manifest an
age-dependent T cell infiltration that progresses with age
and may ultimately be responsible for lethality of Otcasp8 / 
mice by disrupting the function of vital organs such as the
liver, lungs, and kidneys.
Because caspase-8 is located directly downstream of
CD95 in the death receptor pathway, we reasoned that dele-
tion of caspase-8 could lead to an autoimmune lymphoprolif-
erative syndrome (ALPS)-like disease as observed in lpr and
gld mice (12). ALPS is a childhood disorder caused by muta-
tions in the genes encoding CD95, CD95 ligand, and
caspase-10 (12–16). Characterized by chronic lymphoprolif-
eration, ALPS patients also display splenomegaly, lymphoad-
enopathy, and lupus-like phenotypes including increased
circulating immunoglobulins (IgGs) and the presence of au-
toimmune antibodies (14, 17). ALPS is uniquely defined by
resistance to CD95-induced apoptosis and accumulation of
unusual double-negative CD3 B220 CD4 CD8  T cells
(14, 18). Through comparison with lpr mice, we found that
Otcasp8 /  mice do not accumulate double-negative T cells
(Fig. 2 A). Furthermore, increased (IgGs) and the presence
of antinuclear antibodies were not observed in Otcasp8 / 
mice of various ages (Fig. 5, A and B). In lpr disease, immune
complexes are found deposited in glomeruli leading to glo-
merulonephritis (19, 20); no accumulation of immune com-
plexes was observed in the glomeruli of Otcasp8 /  mice
(Fig. 5 C). These findings suggest that the immune disorder
observed in Otcasp8 /  mice is distinct from the ALPS phe-
notype observed in lpr mice.
The phenotype of IL-2 and IL-2R –deficient mice is
similar to tcasp8 /  mice in that young mice show impaired
proliferation and effector functions, and as these mice get
older they show massive enlargement of LNs, spleen, and gut-
associated lymphoid tissue due to polyclonal expansion of T
and B cells (21–24). It has been shown that IL-2 and IL-2R 
are necessary for maintenance of CD4 CD25  regulatory TJEM VOL. 202, September 19, 2005 731
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cells. When analyzed in Otcasp8 /  mice, the proportion of
regulatory T cells was similar to that of littermate control mice
(unpublished data).
Controlled regulation of cell death is essential for lympho-
cyte development and function, and disruption of these pro-
cesses may predispose for immune disorders (1, 25, 26). That
the CD95-mediated death receptor pathway plays an impor-
tant role in the elimination of activated and/or potentially au-
toreactive lymphocytes is underscored in humans where dis-
ruption of CD95 signaling increases the risk for ALPS (27).
We have identified the association of caspase-8 deficiency and
T cell–dependent lymphoproliferation of T and B cell popula-
tions manifested as lymphoadenopathy and splenomegaly. In
addition, we have uncovered nonclonal infiltration of T cells
into the liver, lungs, and kidneys that became more severe
with age and was likely to contribute to the increased lethality
of Otcasp8 /  mice. Finally, Otcasp8 /  mice develop an age-
dependent disease that is distinct from ALPS (or lpr in mice)
and may represent a new form of immune disorder. Interest-
ingly, the condition described in Otcasp8 /  mice manifests
features consistent with the disorder described in humans with
Caspase-8 mutation (5). These findings suggest that tcasp8 / 
mice may serve as an animal model to evaluate Caspase-8 mu-
tant patient prognosis and therapy.
The absence of caspase-8 in T lymphocytes alone is suffi-
cient to provoke an age-dependent and lethal immune disor-
der in mice, a finding that underscores the importance of the
multifunctional role of caspase-8 in apoptosis, cell growth,
and immune homeostasis. We propose a model that argues
that caspase-8 in T cells is required for the maintenance of
lymphocyte homeostasis. When absent in T cells, abnormal
lymphocyte homeostasis emerges, producing T cell lym-
phopenia in young mice, and as mice age, B cell and T cell
compartments expand, producing lymphoproliferation and a
lethal T cell infiltrating disorder.
MATERIALS AND METHODS
Animals. tcasp8 /  (caspase 8fl/fl; Lck-Cre) mice were generated previously
(6). All mice were of a mixed 129J/C57BL/6 genetic background. Lpr mice
were of a C57BL/6 genetic background. PCR genotyping of tcasp8 /  mice
was performed with primer 5 -CCAGGAAAAGATTTGTGTACT-3  and
primer 5 -GGCCTTCCTGAGTACTGTCACCTGT-3 .  Lck-Cre was
identified using primers specific for the cre recombinase gene: 5 -TCGCGAT-
TATCTTCTATATCTTCAG-3  and primer 5 -GCTCGACCAGTT-
TAGTTACCC-3 . All experiments were performed in compliance with the
guidelines of the Ontario Cancer Institute Animal Care Committee.
Flow cytometry. Single-cell suspensions prepared from the thymus,
spleen, and LNs were stained with the indicated antibodies conjugated to
allophycocyanin, phycoerythrin, fluorescein, perCP, or biotin and streptavi-
din-PerCP (BD Biosciences) at 4 C in PBS   10% FCS (GIBCO BRL).
Lymphocytes were analyzed via flow cytometry (FACSCalibur; BD Bio-
sciences) with CellQuest software (Applied Biosystems).
Serology. Tail blood was collected in Vacutainer tubes (Becton Dickin-
son), centrifuged at 14,000 g for 1 min at 4 C to clear sera, and frozen. Se-
rum immunoglobulin (IgG) levels were determined via ELISA according to
the manufacturer’s instructions (Southern Biotechnology). Anti-dsDNA se-
rum levels were also detected via ELISA (Alpha Diagnostic). Serum ALT
and AST levels were measured by the Toronto Medical Laboratories.
Proliferation and cytotoxicity experiments. For in vivo proliferation
analysis, 40-wk-old mice were injected intraperitoneally with 0.6 mg of BrdU
(Sigma-Aldrich) in 200  L of PBS twice daily for 3 d. Lymphocytes were iso-
lated from the spleen and LNs, appropriate cell surface markers were stained as
described above, and BrDU incorporation was revealed with a BrdU-Flow kit
(BD Biosciences). In vitro proliferation analysis and activation-induced cell
death experiments were performed as described previously (6).
Histology, immunohistochemistry, and immunofluorescence. Or-
gans were fixed in buffered formalin, processed for paraffin-embedded
sectioning, and stained with hematoxylin-eosin (Fisher). For immunohis-
tochemistry, paraffin sections were incubated with anti-B220 (BD Bio-
sciences) and/or anti-CD3 (DakoCytomation), anti-CD4 (Serotec) and
anti-CD8 (Serotec) antibodies. Anti-rat horseradish peroxidase (DakoCy-
tomation) and anti–rabbit alkaline phosphatase antibodies (DakoCytoma-
tion) revealed B220 and CD3 double labeling, respectively. Single anti-
body immunohistochemistry staining was revealed with horseradish
peroxidase. Immunoreactivities were revealed via incubation in diamine
benzidine and p-nitrophenylphosphate. In vivo BrdU labeling was re-
vealed via immunohistochemistry using an HRP-linked anti-BrdU anti-
body (Jackson Immunoresearch). Identification of immune complexes in
kidney and other tissues was revealed using a Cy3-conjugated anti–mouse
IgG antibody (Jackson Immunoresearch Laboratories).
Statistical analysis. Data are expressed as the mean   SEM. p-values
were determined using the Student’s t test. Values of P   0.05 were
considered significant.
Online supplemental material. Fig. S1 shows that thymocyte develop-
ment is not affected in old tcasp8 /  mice. Fig. S2 shows no increased T cell
infiltration was observed in nonlymphoid organs, including the brain, heart,
Figure 5. Old tcasp8 /  mice do not manifest systemic lupus 
erythematosus-like autoimmune phenotypes. (A) Levels of circulating 
IgG clonotypes and (B) anti-dsDNA antibodies were analyzed via ELISA in 
tail blood samples. Horizontal bars represent the mean. (C) Representative 
glomeruli from 30-wk-old control and tcasp8 /  mice showing no accu-
mulation of immune complexes compared with lpr mice manifesting high 
levels of glomerular immune complex accumulation.CASPASE-8 DEFICIENCY LEADS TO IMMUNE DISORDER | Salmena and Hakem 732
pancreas, and stomach. Fig. S3 shows polyclonal T cell infiltration in old
tcasp8 /  mice. Fig. S4 shows the expression levels of B cell activation
markers are not affected in Otcasp8 /  mice. Fig. S5 shows in vitro activa-
tion-induced proliferation in Otcasp8 / -derived T cells. Table S1 shows
percentage of T and B cells in the spleen and LNs in control and Otcasp8 / 
mice. Online supplemental material is available at http://www.jem.org/
cgi/content/full/jem.20050683/DC1.
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